Home
News
Create
Screeners
Insights
Fabino Enterprises
20.
31
0.00
(0.00%)
Market Cap
₹4.30 Cr
PE Ratio
-7.64
Industry
Healthcare
Buy
Sell
Company Performance:
1D
0.00%
1M
0.00%
6M
+39.01%
1Y
-21.88%
5Y
-49.67%
View Company Insights
Latest news about Fabino Enterprises
Fabino Enterprises accepts CS Anand Katarmal resignation effective July 7
6 days ago
Fabino Enterprises has accepted the resignation of Anand Katarmal as Company Secretary and Compliance Officer effective July 07, 2026, due to personal reasons. The company will note the resignation at the next Board meeting and announce a successor later.
Fabino Enterprises open offer opens June 29 at ₹20 per share
Jun 25, 2026
Fabino Enterprises open offer to acquire 26% at ₹20 per share
Jun 17, 2026
Fabino FY26 Net Loss Rs 35.97 Cr, Revenue Declines
May 23, 2026
Open Offer for 26.00% Stake in Fabino Enterprises Limited at ₹20 Per Share by R G Family Trust, Sameer Gupta and Sundeep Gupta
May 13, 2026
More news about Fabino Enterprises
06
May 26
Fabino Enterprises Open Offer for 26% Stake at ₹20/Share Scheduled June 22–July 06, 2026
R G Family Trust, Sameer Gupta, and Sundeep Gupta have launched an open offer to acquire 5,46,000 equity shares (26%) of Fabino Enterprises Limited at ₹20 per share, aggregating ₹109.20 Lakhs, under SEBI (SAST) Regulations. The offer is triggered by an SPA dated April 28, 2026 to acquire 56.82% promoter stake at ₹18 per share (₹214.78 Lakhs). The tendering period is scheduled from June 22, 2026 to July 06, 2026, with ₹30,00,000 deposited in escrow with Yes Bank Limited.
11
Apr 26
Fabino Enterprises Ltd. Confirms Non-Applicability of SEBI Large Corporate Framework for FY2027
Fabino Enterprises Ltd. has disclosed to BSE Limited that it does not fall under SEBI's Large Corporate category as of March 31, 2026, exempting it from filing disclosures under the framework for FY2026-27. The company, formerly known as Fabino Life Sciences Ltd., confirmed its non-applicability status through a formal communication signed by Managing Director Aditya Mahavir Jain on April 11, 2026. The disclosure addresses SEBI's revised framework circular dated October 19, 2023, ensuring regulatory compliance and transparency regarding the company's status.
11
Apr 26
Fabino Enterprises Ltd. Submits Q4FY26 Compliance Certificate to BSE
Fabino Enterprises Ltd. submitted its Q4FY26 compliance certificate to BSE on April 11, 2026, confirming non-applicability of SEBI Regulation 74(5) as all company shares remain in dematerialized form. The certificate, issued by registrar Bigshare Services Private Limited, reported no rematerialization or dematerialization requests during the quarter ended March 31, 2026, indicating complete digitization of the shareholding structure.
10
Apr 26
Sushma Shekhar Acquires 8.29% Stake in Fabino Enterprises Through Open Market Purchase
Sushma Shekhar acquired 174,000 shares (8.29%) of Fabino Enterprises Ltd. through open market purchase on April 9, 2026. The acquirer, who is not part of the promoter group, previously held no shares in the BSE-listed company. The acquisition has been disclosed under SEBI Regulation 29, with the company's equity capital remaining at INR 2,10,00,000 divided into 21,00,000 shares of INR 10 each.
26
Dec 25
Fabino Enterprises Independent Director Mr. Kuldeep Solanki Resigns with Immediate Effect
Fabino Enterprises Limited announced the immediate resignation of Non-Executive Independent Director Mr. Kuldeep Solanki (DIN: 07109951) effective December 26, 2025, citing pre-occupation and personal commitments. The company has informed BSE Limited under Regulation 30 of SEBI Listing Regulations and confirmed that succession planning will be addressed in the upcoming Board meeting.
26
Dec 25
Fabino Enterprises Appoints Deepali Singla as Independent Director
Fabino Enterprises Limited has appointed Mrs. Deepali Singla (DIN: 11442242) as Additional Non-Executive Independent Director effective December 26, 2025, following a board meeting. She brings over six years of professional experience as an Associate at United Lex, specializing in document review, legal research, and regulatory compliance with exposure to Supreme Court and Delhi High Court proceedings.
Fabino Enterprises
20.
31
0.0
(0.0%)
1 Year Returns:
-21.88%
Industry Peers
Sun Pharmaceutical
1,932.80
(+
0.
59
%)
Divis Laboratories
6,945.00
(+
0.
09
%)
Torrent Pharmaceuticals
4,988.30
(+
0.
75
%)
Cipla
1,439.80
(+
0.
92
%)
Zydus Life Science
1,137.90
(+
0.
58
%)
Lupin
2,496.70
(+
0.
16
%)
Mankind Pharma
2,516.50
(+
0.
36
%)
Dr Reddys Laboratories
1,241.40
(+
0.
56
%)
Aurobindo Pharma
1,565.20
(+
1.
03
%)
Laurus Labs
1,557.00
(-
0.
10
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar